Babak Razani

Babak Razani

Auto-generated profile, based on publicly available information

Babak Razani

University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center (UPMC), PA (B.R.).

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Immunity
Verified
Journal Article
Closed access
SESlava Epelman
Slava Epelman
KLKory J. Lavine
Kory J. Lavine
ABAnna E. Beaudin
Anna E. Beaudin
DSDorothy K. Sojka
Dorothy K. Sojka
JCJavier A. Carrero
Javier A. Carrero
DMDouglas L Mann
Douglas L Mann

1 October 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BRBabak Razani
Babak Razani
JEJeffery A. Engelman
Jeffery A. Engelman
XWXiao Bo Wang
Xiao Bo Wang
WSWilliam Schubert
William Schubert
XZXiao Lan Zhang
Xiao Lan Zhang
MLMichael P. Lisanti
Michael P. Lisanti
Caveolin-1 is the principal structural protein of caveolae membranes in fibroblasts and endothelia. Recently, we have shown that the human CAV-1 gene is localized to a suspected tumor suppressor locus, and mutations in Cav-1 have been implicated in human cancer. Here, we created a caveolin-1 null (CAV-1 −/−) mouse model, using standard homologous recombination techniques, to assess the role of caveolin-1 in caveolae biogenesis, endocytosis, cell proliferation, and endothelial nitric-oxide synthase (eNOS) signaling. Surprisingly, Cav-1 null mice are viable. We show that these mice lack caveolin-1 protein expression and plasmalemmal caveolae. In addition, analysis of cultured fibroblasts from Cav-1 null embryos reveals the following: (i) a loss of caveolin-2 protein expression; (ii) defects in the endocytosis of a known caveolar ligand, i.e.fluorescein isothiocyanate-albumin; and (iii) a hyperproliferative phenotype. Importantly, these phenotypic changes are reversed by recombinant expression of the caveolin-1 cDNA. Furthermore, examination of the lung parenchyma (an endothelial-rich tissue) shows hypercellularity with thickened alveolar septa and an increase in the number of vascular endothelial growth factor receptor (Flk-1)-positive endothelial cells. As predicted, endothelial cells from Cav-1 null mice lack caveolae membranes. Finally, we examined eNOS signaling by measuring the physiological response of aortic rings to various stimuli. Our results indicate that eNOS activity is up-regulated in Cav-1 null animals, and this activity can be blunted by using a specific NOS inhibitor, nitro-l-arginine methyl ester. These findings are in accordance with previous in vitro studies showing that caveolin-1 is an endogenous inhibitor of eNOS. Thus, caveolin-1 expression is required to stabilize the caveolin-2 protein product, to mediate the caveolar endocytosis of specific ligands, to negatively regulate the proliferation of certain cell types, and to provide tonic inhibition of eNOS activity in endothelial cells.

1 September 2002 in Pharmacological Reviews
Verified
Journal Article
Closed access
BRBabak Razani
Babak Razani
SWScott E. Woodman
Scott E. Woodman
MLMichael P. Lisanti
Michael P. Lisanti
Among the membrane compartments of a cell, vesicles known as "caveolae" have long defied functional characterization. However, since the identification of a family of proteins termed "caveolins", that form and reside in caveolae, a better understanding has emerged. It is now clear that caveolae do not merely play a singular role in the cell, but are pleiotropic in nature-serving to modulate many cellular functions. The purpose of this review is to explicate what is known about caveolins/caveolae and highlight growing areas of caveolar research.

1 March 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BRBabak Razani
Babak Razani
XZXiao Lan Zhang
Xiao Lan Zhang
MBMarkus Bitzer
Markus Bitzer
GGGero von Gersdorff
Gero von Gersdorff
EBErwin P. Böttinger
Erwin P. Böttinger
MLMichael P. Lisanti
Michael P. Lisanti
Transforming growth factor-β (TGF-β) signaling proceeds from the cell membrane to the nucleus through the cooperation of the type I and II serine/threonine kinase receptors and their downstream SMAD effectors. Although various regulatory proteins affecting TGF-β-mediated events have been described, relatively little is known about receptor interactions at the level of the plasma membrane. Caveolae are cholesterol-rich membrane microdomains that, along with their marker protein caveolin-1 (Cav-1), have been implicated in the compartmentalization and regulation of certain signaling events. Here, we demonstrate that specific components of the TGF-β cascade are associated with caveolin-1 in caveolae and that Cav-1 interacts with the Type I TGF-β receptor. Additionally, Cav-1 is able to suppress TGF-β-mediated phosphorylation of Smad-2 and subsequent downstream events. We localize the Type I TGF-β receptor interaction to the scaffolding domain of Cav-1 and show that it occurs in a physiologically relevant time frame, acting to rapidly dampen signaling initiated by the TGF-β receptor complex.

1 April 2012 in Cell Metabolism
Verified
Journal Article
Closed access
BRBabak Razani
Babak Razani
CFChu Feng
Chu Feng
TCTrey Coleman
Trey Coleman
RERoy Emanuel
Roy Emanuel
HWHaitao Wen
Haitao Wen
CSClay F. Semenkovich
Clay F. Semenkovich

1 March 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BRBabak Razani
Babak Razani
TCTerry P. Combs
Terry P. Combs
XWXiao Bo Wang
Xiao Bo Wang
PFPhilippe G Frank
Philippe G Frank
DPDavid S. Park
David S. Park
MLMichael P. Lisanti
Michael P. Lisanti
Caveolae organelles and caveolin-1 protein expression are most abundant in adipocytes and endothelial cells. Our initial report on mice lacking caveolin-1 (Cav-1) demonstrated a loss of caveolae and perturbations in endothelial cell function. More recently, however, observation of the Cav-1-deficient cohorts into old age revealed significantly lower body weights, as compared with wild-type controls. These results suggest that Cav-1 null mice may have problems with lipid metabolism and/or adipocyte functioning. To test this hypothesis directly, we placed a cohort of wild-type and Cav-1 null mice on a high fat diet. Interestingly, despite being hyperphagic, Cav-1 null mice show overt resistance to diet-induced obesity. As predicted, adipocytes from Cav-1 null null mice lack caveolae membranes. Early on, a lack of caveolin-1 selectively affects only the female mammary gland fat pad and results in a near complete ablation of the hypo-dermal fat layer. There are also indications of generalized adipose tissue pathology. With increasing age, a systemic decompensation in lipid accumulation occurs resulting in dramatically smaller fat pads, histologically reduced adipocyte cell diameter, and a poorly differentiated/hypercellular white adipose parenchyma. To gain mechanistic insights into this phenotype, we show that, although serum insulin, glucose, and cholesterol levels are entirely normal, Cav-1 null mice have severely elevated triglyceride and free fatty acid levels, especially in the post-prandial state. However, this build-up of triglyceride-rich chylomicrons/very low density lipoproteins is not due to perturbed lipoprotein lipase activity, a major culprit of isolated hypertriglyceridemia. The lean body phenotype and metabolic defects observed in Cav-1 null mice are consistent with the previously proposed functions of caveolin-1 and caveolae in adipocytes. Our results show for the first time a clear role for caveolins in systemic lipid homeostasis in vivo and place caveolin-1/caveolae as major factors in hyperlipidemias and obesity.